AOD-9604 vs Tirzepatide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191
A modified fragment of human growth hormone (amino acids 177-191) studied for fat metabolism effects without the broader hormonal effects of full GH.
Also: Mounjaro, Zepbound
A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.
Key Comparison Insights
- Tirzepatide is FDA approved, while AOD-9604 remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Tirzepatide has stronger research evidence (FDA Approved) compared to AOD-9604 (Human Trials).
Detailed Comparison
| Attribute | AOD-9604 | Tirzepatide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | AOD-9604 mimics the lipolytic (fat-burning) effects of growth hormone without affecting blood sugar or tissue growth. It stimulates lipolysis and inhibits lipogenesis by interacting with beta-3 adrenergic receptors on fat cells. | Tirzepatide activates both GLP-1 and GIP receptors, providing synergistic effects on appetite suppression, insulin secretion, and metabolic regulation. The dual mechanism enhances glucose-dependent insulin release while reducing glucagon and slowing gastric emptying. |
| Common Dosing | 300 mcg daily Once daily, usually morning fasted | 5-15 mg weekly (after titration) Once weekly |
| Administration | Subcutaneous injection or oral (studied both) | Subcutaneous injection weekly |
| Typical Duration | 12-24 weeks in studies | Long-term / chronic use |
| Best Time to Take | Morning (fasted) | Morning, same day each week |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Clinical trials showed modest weight loss effects but failed to meet primary endpoints for FDA approval. Some studies show cartilage regeneration potential. Research demonstrates safety profile similar to placebo with no significant GH-like side effects. | SURMOUNT trials showed average weight loss of 20-26% body weight. SURMOUNT-OSA showed 25-29 fewer sleep apnea events per hour. SURPASS-2 showed superior A1C reduction compared to semaglutide. SUMMIT trial (2024-25) showed 38% reduction in CV death or worsening heart failure in HFpEF patients with obesity - data added to EU labeling Jan 2026. |
Frequently Asked Questions: AOD-9604 vs Tirzepatide
What is the difference between AOD-9604 and Tirzepatide?
AOD-9604 is a weight loss peptide that a modified fragment of human growth hormone (amino acids 177-191) studied for fat metabolism effects without the broader hormonal effects of full gh. Tirzepatide is a weight loss peptide that a dual gip/glp-1 receptor agonist representing the next generation of incretin-based therapies. shows superior weight loss compared to semaglutide in head-to-head trials. first medication approved for obstructive sleep apnea. The main differences lie in their mechanisms of action and clinical applications.
Which is better, AOD-9604 or Tirzepatide?
Neither is universally "better" - the choice depends on your specific goals. AOD-9604 is typically used for weight loss purposes, while Tirzepatide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can AOD-9604 and Tirzepatide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using AOD-9604 and Tirzepatide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.